Peer-influenced content. Sources you trust. No registration required. This is HCN.
Oncology News Central (ONC)
In SAFFRON, median overall survival reached 17.8 months with dual EGFR/MET inhibition versus 12.9 months with chemotherapy. Results apply to patients with MET overexpression and/or amplification after osimertinib progression, not all EGFR-mutated NSCLC.
Medical Oncology November 11th 2026
News Medical
Radiation shifted protective innate lymphoid cells toward an inflammatory state in preclinical experiments. Disrupting interferon signaling reduced lung injury and fibrosis in mice, but the study did not establish benefit in patients.
Medical Xpress
A patient with advanced, treatment-resistant lung cancer experienced complete tumor disappearance after sodium selenite treatment and remained tumor-free for 10 years. The single case cannot establish efficacy, safety, or causality.
Internal Medicine September 2nd 2026
Oncology Nurse Advisor
“The extended-hours model was effective… early morning dose, in-center observation, overnight remote monitoring equipment, and next-day follow-up cut the need for extended shifts and differential pay.”
Oncology Nursing June 10th 2026
Cancer Therapy Advisor
A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.
Hematology/Oncology May 26th 2026
MDLinx
Invasive mucinous adenocarcinoma carries elevated NRG1 fusion burden that standard DNA-based sequencing reliably misses, while an FDA-approved targeted therapy now exists for confirmed cases.
Hematology/Oncology May 12th 2026